IMBCR & Emory University’s Big Discovery!

Multiple myeloma (MM) patients are at higher risk for severe COVID-19. Their mRNA vaccination response…

read more

James R. Berenson, MD, Inc. Announces Rebranding and Changes Organization Name to Berenson Cancer Center

New name, logo, and business unit alignment introduced as part of an extensive rebranding initiative…

read more

Efficacy and Safety of Ruxolitinib and Steroids for Treating Patients with Relapsed or Refractory Multiple Myeloma (RRMM). Results from the I-RUX Study Published in ASH2020

January 19, 2021 WEST HOLLYWOOD, CA, January 19, 2021 – ONCOtherapeutics and Dr. James Berenson…

read more

James R. Berenson, MD, Inc. Announces Rebranding and Changes Organization Name to Berenson Cancer Center

New name, logo, and business unit alignment introduced as part of an extensive rebranding initiative…

read more